| Date Filed | Type | Description |
| 03/28/2023 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities: |
| 03/09/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/02/2023 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 02/27/2023 |
4
| Appelhans Dannielle (CEO and President) has filed a Form 4 on Rubius Therapeutics, Inc.|
Txns:
| Sold 10,385 shares
@ $0.1274, valued at
$1.3k
|
|
| 02/27/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/27/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/27/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/27/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/27/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/27/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2023 |
RW
| Form RW - Registration Withdrawal Request: |
| 02/22/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Flagship VentureLabs IV, LLC reports a 42.7% stake in Rubius Therapeutics, Inc. |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 13.7% stake in RUBIUS THERAPEUTICS INC |
| 02/06/2023 |
8-K
| Quarterly results |
| 02/01/2023 |
4
| CAGNONI PABLO J (Director) has filed a Form 4 on Rubius Therapeutics, Inc.|
Txns:
| Sold 8,448 shares
@ $0.25, valued at
$2.1k
|
|
| 02/01/2023 |
4
| Appelhans Dannielle (CEO and President) has filed a Form 4 on Rubius Therapeutics, Inc.|
Txns:
| Sold 3,878 shares
@ $0.25, valued at
$969.5
Exercised 7,500 restricted stock units
@ $0 |
|
| 01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/20/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/21/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
8-K
| Quarterly results |
| 12/12/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/02/2022 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 10/17/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/13/2022 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 09/13/2022 |
8-K
| Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits Interactiv... |
| 08/12/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
4
| Appelhans Dannielle (COO) has filed a Form 4 on Rubius Therapeutics, Inc.|
Txns:
| Sold 5,737 shares
@ $0.8, valued at
$4.6k
Exercised 12,500 restricted stock units
@ $0 |
|
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 08/01/2022 |
4
| Schaffert Susanne (Director) has filed a Form 4 on Rubius Therapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $0.702, valued at
$35.1k
|
|
|